PEG-MGF for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

PEG-MGF for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A lab-made peptide meant to copy and outlast a natural muscle-repair signal. Hoped benefits for muscle recovery, age-related muscle loss, and tissue repair remain unproven — backed only by cell and animal work, with no human trials. Sold as an unregulated research chemical with real contamination and possible tumor-promoting risks, and banned in competitive sport. (Full Review)

Protocol

Dose
200–400 mcg
Subcutaneous, per administration; reconstituted from lyophilized powder with bacteriostatic water
Frequency
A few times weekly
Long-acting; given as a single dose per injection day, not split
Timing
Post-workout / training days
Theorized to complement exercise-induced muscle damage; no pharmacodynamic data support any time of day
Time to effect
Subjective recovery
Days to weeks
Anecdotal, around training; uncontrolled impressions, no validated timeframe or measured outcomes

Benefits

Contraindications
  • Active or prior cancer (especially prostate, colorectal, endometrial, or bone)
  • Active diabetic retinopathy or proliferative eye disease
  • Pregnant or breastfeeding individuals
  • Adolescents and anyone with open growth plates
  • Competitive athletes subject to anti-doping rules
  • Known PEG hypersensitivity
    •
Key Interactions
  • Growth hormone and IGF-1 (prescription/gray-market)
  • Insulin and glucose-lowering drugs (sulfonylureas such as glipizide, insulin)
  • Supplements with additive growth/IGF effects (high-dose colostrum, IGF-1 LR3, anabolic peptides)
  • Anabolic-androgenic steroids and other performance peptides
    •

Risk & Side Effects

  • High: Unregulated product: contamination, mislabeling, and impurity
    •
  • Medium: Theoretical cancer-promotion / tumor growth
    •
  • Low: IGF-1-type metabolic and growth effects; injection-related local reactions
    •
  • Speculative: Cardiac and other off-target effects
    •

Monitoring

Marker Target Why
IGF-1 Mid-normal, age-adjusted (~100–200 ng/mL in mid-life adults) Tracks growth-axis exposure; guards against pushing IGF signaling too high
Fasting glucose 75–90 mg/dL Detects hypoglycemia from IGF-1-like activity
HbA1c < 5.4% Longer-term glucose control if used repeatedly
PSA < 1.0 ng/mL (age-dependent) Screens for prostate proliferation given IGF-1Ec's cancer association
hs-CRP < 1.0 mg/L Flags injection-site or systemic inflammatory reactions
CBC Within normal limits Baseline safety and infection screen given injectable use

Cadence: Baseline, at ~4–6 weeks, and every 3–6 months during any continued use

Qualitative Assessment

  • Perceived recovery and muscle soreness after training
  • Energy and subjective well-being
  • Any new joint or soft-tissue swelling
  • Injection-site appearance (redness, lump, pain) as an infection or reaction signal
  • Any unexplained symptoms warranting cancer evaluation
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.